Imunon, Inc. (0HUZ.L)

1.1007 -0.4243 (-27.82%) At close: 05:21PM BST

Imunon, Inc.

997 Lenox Drive
Suite 100
Lawrenceville, NJ 08648
United States
609 896 9100
https://www.imunon.com

Sector(s): 
Industry: 
Full-time employees: 33

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Michael H. Tardugno	Executive Chairman	N/A	N/A	1951
Mr. Jeffrey W. Church CPA	CFO, Executive VP & Corporate Secretary	632.02k	N/A	1957
Dr. Khursheed Anwer M.B.A., Ph.D.	Executive VP & Chief Scientific Officer	632.26k	N/A	1960
Mr. Timothy J. Tumminello CPA	Chief Accounting Officer & Controller	108.31k	N/A	1958
Ms. Marianne M. Lambertson	Vice President of Communications & Investor Relations	N/A	N/A	N/A
Dr. Sebastien Hazard M.D.	Executive VP & Chief Medical Officer	N/A	N/A	1972

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Imunon, Inc., a clinical stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The Company's lead clinical programs comprise IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development; and ThermoDox for the treatment of hepatocellular carcinoma. It also has two platform technologies, such as TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies; and PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The company was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. Imunon, Inc. was founded in 1982 and is based in Lawrenceville, New Jersey.

Corporate governance

Imunon, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.